キノキサリンベースのUCHL5阻害剤は,20S阻害を超えて,次世代のタンパク質を標的とする抗がん剤として使用されています
Tae-Hee Han1, Joohan Lee2, Joo-Young Im3
1Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, South Korea; Department of Biomolecular Science, KRIBB School of Bioscience, Korea National University of Science and Technology (UST), Daejeon 34113, South Korea.
Journal of advanced research
|February 12, 2026
まとめ
新種のキノキサリン誘導体であるDK-7は,プロテアソームの成分であるUCHL5を選択的に抑制する. この化合物は,がん細胞のアポプトシスを効果的に誘発し,ボルテゾミブ耐性を克服し,固体腫瘍治療の有望性を示しています.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- 癌細胞は,生存のために,エンドプラズマ網膜 (ER) ストレスと展開タンパク質応答 (UPR) を利用します.
- ウビキチン-プロテアソーム系 (UPS) は,タンパク質の恒常性にとって極めて重要であり,腫瘍ではしばしば制御不能である.
- 既存のプロテアソーム阻害剤は,固体腫瘍および獲得抵抗における有効性の制限に直面しています.
研究 の 目的:
- UCHL5を標的にするキノキサリンベースの分子を発見すること,これはプロテアソームの調節粒子成分です.
- がんにおけるボルテゾミブ耐性を克服するこれらの分子の可能性を評価する.
- 鉛化合物の作用機構と抗がん効果を特徴付ける.
主な方法:
- ERストレス誘導のためのクイノキサリン誘導体ライブラリのスクリーニング.
- 酵素測定,生体結合,分子ドッキング,および質量スペクトロメトリを使用して,UCHL5の標的を特定し,検証します.
- ボルテゾミブ耐性モデルを含む様々な癌細胞系における抗癌活性に関するインビトロ評価.
- 異種移植マウスモデルを用いたin vivo評価.
主要な成果:
- キノキサリン誘導体であるDK-7は,強力で選択的なUCHL5阻害剤として特定されました.
- DK-7は20Sプロテアゾームの活性を抑制することなく,ユビキチン化タンパク質の蓄積,ERストレス,アポトーシスを誘発した.
- DK-7は,固体腫瘍およびボルテゾミブ耐性多発性骨髄腫細胞における細胞活性の有意な低下を示した.
- 口服によるDK-7投与は,異種移植モデルにおける腫瘍の成長を抑制した.
結論:
- DK-7は選択的にUCHL5を標的にし,ERストレスとアポトーシスを誘発し,ボルテゾミブ耐性を克服します.
- UCHL5抑制は,固体腫瘍に対する有望な治療戦略です.
- キノキサリンベースのデウビキキチナゼ阻害剤は,広範な臨床適用性を持つ,次世代のプロテアソームを標的とした潜在的な治療法を提供します.
キーワード:
19Sプロテアソマルデウビキチナゼ UCHL55ボルテゾミブに対する耐性があります.プロテアソーム阻害剤 プロテアソーム阻害剤キノキサリンベースの小分子DK-7ウビキチンプロテアソームシステムさらに関連する動画
関連する概念動画
The Proteasome
10.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.3K
The Proteasome
1.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
The Proteasome
4.6K
4.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
597
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
597
Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
The Proteasome Structure
1.8K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.8K


